Evidence map›Paper›PMID 36763690›Full record

ArticlePloS one2023

A novel assay for improved detection of sputum periostin in patients with asthma.

Junya Ono, Masayuki Takai, Ayami Kamei, Shoichiro Ohta, Parameswaran Nair, Kenji Izuhara, Sven-Erik Dahlén, Anna James, BIOAIR consortium

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. The Past, the Present, and the Future of Periostin in Allergy.Allergy, asthma & immunology research · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Junya OnoShino-Test Corporation Ltd., Sagamihara, Japan.
Masayuki TakaiShino-Test Corporation Ltd., Sagamihara, Japan.
Ayami KameiShino-Test Corporation Ltd., Sagamihara, Japan.
Shoichiro OhtaDepartment of Laboratory Medicine, Saga Medical School, Saga, Japan.
Parameswaran NairDepartment of Medicine, Division of Respirology, McMaster University and Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, Ontario, Canada.
Kenji IzuharaDivision of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan.
Sven-Erik DahlénExperimental Asthma and Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Anna JamesExperimental Asthma and Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
BIOAIR consortium
Shino-Test CorporationKarolinska Institutet · SESaga Medical School Hospital · JPMcMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSerum periostin associates with type-2 inflammation in asthmatic airways, but also reflects whole body periostin levels originating from multiple sources. Less is known about sputum periostin as a biomarker in asthma as detection levels are low using currently available periostin assays. We aimed to investigate detection of sputum periostin using ELISA assays targeting different periostin epitopes and relate levels to clinical characteristics.

methodsTwo ELISA systems were developed using antibodies detecting whole periostin or cleavage products, the molecular weight and amino acid sequences of which were confirmed. The ELISA assays were applied to sputum from 80 patients with mild-to-moderate and severe asthma enrolled in the European, multi-center study BIOAIR. Results were related to clinical characteristics.

resultsSputum was found to contain smaller periostin fragments, possibly due to proteolytic cleavage at a C-terminal site. Comparing ELISA methodology using antibodies against cleaved versus whole periostin revealed detectable levels in 90% versus 44% of sputum samples respectively. Sputum periostin showed associations with blood and sputum eosinophils. Furthermore, sputum, but not serum, periostin correlated with reduced lung function and sputum IL-13 and was reduced by oral corticosteroid treatment.

conclusionsWe present an ELISA method for improved analysis of sputum periostin by detecting cleavage products of the periostin protein. Using this assay, sputum periostin was detectable and associated with more disease-relevant parameters in asthma than serum periostin. Sputum periostin is worth considering as a phenotype-specific biomarker in asthma as its proximity to the airways may eliminate some of the confounding factors known to affect serum periostin.

Indexed as

AsthmaSputumBiomarkersEosinophilsHumansPhenotypeBiomarkers

Identifiers

PMID36763690
PMCPMC9916630
OpenAlexW4319879874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.